Asunaprevir recipients , achieving protocol-defined response ( HCV-RNA below quantification limit at week @ and undetectable at week @ ) , were rerandomized at week @ to continue asunaprevir-based triple therapy or receive placebo plus PegIFN/RBV for weeks @-@ .